4.
ROC curves for CA125, HE4, ROMA and CPH-I for differentiating non-epithelial ovarian cancers and borderline ovarian tumors from benign ovarian mass.
| Group | Tests | AUC(95%CI) | SN(%) | SP(%) | PPV(%) | NPV(%) |
| OC+BOT (n=188) vs Benign (n=531) | ||||||
| Early stage | CA125 | 0.678 (0.615, 0.740) | 55.2 | 72.9 | 26.9 | 90.0 |
| HE4 | 0.756 (0.695, 0.816) | 33.3 | 94.4 | 51.6 | 88.7 | |
| ROMA | 0.758 (0.698, 0.818) | 50.0 | 87.6 | 42.1 | 90.6 | |
| CPH-I | 0.751 (0.693, 0.810) | 40.6 | 94.7 | 58.2 | 89.8 | |
| Advanced stage | CA125 | 0.911 (0.875, 0.947) | 85.9 | 72.9 | 35.4 | 96.8 |
| HE4 | 0.957 (0.928, 0.986) | 81.5 | 94.4 | 71.4 | 96.7 | |
| ROMA | 0.959 (0.930, 0.988) | 89.1 | 87.6 | 55.4 | 97.9 | |
| CPH-I | 0.961 (0.937, 0.985) | 88.0 | 94.7 | 74.3 | 97.9 | |
| EOC (n=119) vs Benign (n=531) | ||||||
| Early stage | CA125 | 0.790 (0.693, 0.888) | 70.3 | 72.9 | 15.3 | 97.2 |
| HE4 | 0.869 (0.783, 0.954) | 67.6 | 94.4 | 45.5 | 97.7 | |
| ROMA | 0.866 (0.780, 0.953) | 73.0 | 87.6 | 29.0 | 97.9 | |
| CPH-I | 0.855 (0.769, 0.940) | 67.6 | 94.7 | 47.2 | 97.7 | |
| Advanced stage | CA125 | 0.933 (0.901, 0.965) | 90.2 | 72.9 | 33.9 | 98.0 |
| HE4 | 0.981 (0.962, 0.999) | 85.4 | 94.4 | 70.0 | 97.7 | |
| ROMA | 0.983 (0.965, 1.000) | 93.9 | 87.6 | 53.8 | 98.9 | |
| CPH-I | 0.983 (0.970, 0.996) | 92.7 | 94.7 | 73.1 | 98.8 | |
| EOC (n=119) vs Non-EOC+BOT (n=69) | ||||||
| Early stage | CA125 | 0.741 (0.624, 0.857) | 70.3 | 54.2 | 49.1 | 74.4 |
| HE4 | 0.791 (0.685, 0.896) | 67.6 | 88.1 | 78.1 | 81.2 | |
| ROMA | 0.781 (0.674, 0.889) | 73.0 | 64.4 | 56.2 | 79.2 | |
| CPH-I | 0.783 (0.673, 0.893) | 67.6 | 76.3 | 64.1 | 78.9 | |
| Advanced stage | CA125 | 0.779 (0.617, 0.941) | 90.2 | 50.0 | 93.7 | 38.5 |
| HE4 | 0.856 (0.736, 0.976) | 85.4 | 50.0 | 93.3 | 29.4 | |
| ROMA | 0.876 (0.754, 0.997) | 93.9 | 50.0 | 93.9 | 50.0 | |
| CPH-I | 0.868 (0.761, 0.976) | 92.7 | 50.0 | 93.8 | 45.5 | |